2020
DOI: 10.1097/mjt.0000000000001150
|View full text |Cite
|
Sign up to set email alerts
|

Ruxolitinib Discontinuation Syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 18 publications
0
1
0
Order By: Relevance
“…As stated above, ruxolitinib doses and timing of administration greatly influence the immune state, the subsequent pathogen clearance and survival [84]. Besides, a withdrawal syndrome is described when patients cease ruxolitinib treatment, which is termed "ruxolitinib discontinuation syndrome" and can lead to a cytokine storm that could be highly detrimental in a context of sepsis [89].…”
Section: Modulators Of the Jak-stat Pathways And Applicability In Sepsismentioning
confidence: 99%
“…As stated above, ruxolitinib doses and timing of administration greatly influence the immune state, the subsequent pathogen clearance and survival [84]. Besides, a withdrawal syndrome is described when patients cease ruxolitinib treatment, which is termed "ruxolitinib discontinuation syndrome" and can lead to a cytokine storm that could be highly detrimental in a context of sepsis [89].…”
Section: Modulators Of the Jak-stat Pathways And Applicability In Sepsismentioning
confidence: 99%